Latest News and Press Releases

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater...

Santhera ernennt Marc Clausse zum Chief Commercial Officer, um die nächste Wachstumsphase voranzutreiben

Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth

CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...

CORAL GABLES, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

Markteinführung in der Schweiz für das zweite Halbjahr 2026 erwartet Pratteln, Schweiz, 15. Januar 2026 – Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass die Schweizerische Heilmittelbehörde...

Commercial launch in Switzerland anticipated in H2 2026 Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products...

Entrada Therapeutics reports progress across its portfolio of RNA-based programs for the potential treatment of neuromuscular and ocular diseases.

Ad-hoc-Mitteilung gemäss Art. 53 KR Die exklusive Lizenzvereinbarung umfasst eine Vorauszahlung in Höhe von 40 Millionen US-Dollar, bestehend aus 30 Millionen US-Dollar in bar und einer...